LLY
Eli Lilly and Company
LLY has the edge over OPRX overall, supported by lower modeled downside and stronger modeled upside.
OPRX
OptimizeRx Corporation
OPRX's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OPRX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Strong |
OPRX's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.2x | $8.87 | — |
| Cheap | 20x | $4.88 | -45% |
| Current | 37x | $8.87 | — |
| Fair | 592x | $142 | +1503% |
| Expensive | 1,627x | $391 | +4303% |
Historical ranges are pointers, not guarantees.
OPRX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for OPRX, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OPRX on earnings, with more consistent year-over-year improvement.
OPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.97 | +304% |
| Q2 2026 | $0.24 | +$0.78 |
| Q1 2026 | $0.36 | +$1.20 |
| Q4 2025 | $0.27 | +$1.37 |
| Q3 2025 | $0.00 | +$1.35 |
| Q2 2025 | -$0.54 | +$0.48 |
| Q1 2025 | -$0.84 | +$0.20 |
| Q4 2024 | -$1.10 | -$0.07 |
| Q3 2024 | -$1.35 | -$0.54 |
OPRX has returned to profit: it earned $0.24 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OPRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OPRX on profitability, with a higher operating margin.
OPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.5M | -30% |
| Q1 2026 | $19.8M | -9.5% |
| Q4 2025 | $32.2M | -0.2% |
| Q3 2025 | $26.1M | +22% |
| Q2 2025 | $29.2M | +2307% |
| Q1 2025 | $21.9M | +1168770% |
| Q4 2024 | $32.3M | +14% |
| Q3 2024 | $21.3M | +30% |
OPRX's revenue has slid since its 2024 peak: $21M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -0.4% | -11 points |
| Q1 2026 | 2% | +12 points |
| Q4 2025 | 27% | +15 points |
| Q3 2025 | 7.9% | +48 points |
| Q2 2025 | 11% | +320 points |
| Q1 2025 | -9.6% | +268061 points |
| Q4 2024 | 11% | +50 points |
| Q3 2024 | -40% | -18 points |
OPRX's operating margin was −0.4% last quarter, down 11 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
OPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $8.6M | +88% |
| Q1 2026 | -$488K | -113% |
| Q4 2025 | $7.1M | +3810% |
| Q3 2025 | $3.2M | +80% |
| Q2 2025 | $4.6M | +518% |
| Q1 2025 | $3.8M | +84% |
| Q4 2024 | $181K | +$6.4M |
| Q3 2024 | $1.8M | +23% |
OPRX has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +24K shares |
| 1 year | -1.2% | -230K shares |
| 3 years | +11% | +1.8M shares |
| 5 years | +3.8% | +681K shares |
| Available history | +33% | +4.6M shares |
OPRX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | $7.5M |
| Q4 2022 | $7.5M |
| Q3 2022 | $12.2M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 23.5x | High |
OPRX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 77.6 | Neutral |
OPRX's weekly RSI is 57 (neutral) and its Stochastic is 78 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OPRX PE vs Healthcare Sector
| Metric | OPRX | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 43% above |
| PE % | 45 | 29 | 16 pts above |
OPRX has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over OPRX on trend strength, trading above more of its moving averages.
OPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.69 | 2.1% above |
| 20 week MA | $7.75 | 14% above |
| 50 week MA | $8.11 | 9.4% above |
| 100 week MA | $10.1 | 12% below |
| 200 week MA | $10.7 | 17% below |
OPRX has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 17% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OPRX on returns for 2026, with the stronger performance.
OPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.1 | $31.6 | +214% |
| 2021 | $31.6 | $60.5 | +92% |
| 2022 | $60.5 | $16.7 | -72% |
| 2023 | $16.7 | $14.3 | -14% |
| 2024 | $14.3 | $5.09 | -64% |
| 2025 | $5.09 | $12.5 | +145% |
| 2026 YTD | $12.5 | $8.87 | -29% |
OPRX's yearly returns have swung widely, from +214% in 2020 to −72% in 2022. It's down 29% so far in 2026.